Protalix BioTherapeutics Inc (PLX)
2.23
+0.09
(+4.21%)
USD |
NYAM |
Jun 02, 16:00
2.23
0.00 (0.00%)
After-Hours: 17:23
Protalix BioTherapeutics Revenue (TTM): 41.14M for March 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| March 31, 2023 | 41.14M |
| December 31, 2022 | 47.64M |
| September 30, 2022 | 47.57M |
| June 30, 2022 | 45.44M |
| March 31, 2022 | 43.12M |
| December 31, 2021 | 38.35M |
| September 30, 2021 | 49.30M |
| June 30, 2021 | 48.03M |
| March 31, 2021 | 52.57M |
| December 31, 2020 | 62.90M |
| September 30, 2020 | 61.16M |
| June 30, 2020 | 64.62M |
| March 31, 2020 | 65.90M |
| December 31, 2019 | 54.69M |
| September 30, 2019 | 47.29M |
| June 30, 2019 | 45.37M |
| March 31, 2019 | 37.96M |
| December 31, 2018 | 34.24M |
| September 30, 2018 | 28.19M |
| June 30, 2018 | 23.38M |
| March 31, 2018 | 24.90M |
| December 31, 2017 | 21.08M |
| September 30, 2017 | 18.85M |
| June 30, 2017 | 16.00M |
| March 31, 2017 | 11.41M |
| Date | Value |
|---|---|
| December 31, 2016 | 9.199M |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | -5.889M |
| June 30, 2015 | -3.518M |
| March 31, 2015 | -2.168M |
| December 31, 2014 | 3.523M |
| September 30, 2014 | 3.385M |
| June 30, 2014 | 3.037M |
| March 31, 2014 | 3.415M |
| December 31, 2013 | 0.00 |
| September 30, 2013 | 10.44M |
| June 30, 2013 | 12.47M |
| March 31, 2013 | 34.66M |
| December 31, 2012 | 34.42M |
| September 30, 2012 | 35.06M |
| June 30, 2012 | 30.57M |
| March 31, 2012 | 6.078M |
| December 31, 2011 | 8.35M |
| September 30, 2011 | 13.44M |
| June 30, 2011 | 15.73M |
| March 31, 2011 | 16.10M |
| December 31, 2010 | 10.95M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
23.38M
Minimum
Jun 2018
65.90M
Maximum
Mar 2020
46.94M
Average
47.43M
Median
Revenue (TTM) Benchmarks
| Lexicon Pharmaceuticals Inc | 0.126M |
| AIM ImmunoTech Inc | 0.156M |
| Perspective Therapeutics Inc | 7.887M |
| Electromed Inc | 45.72M |
| Armata Pharmaceuticals Inc | -- |